Skip to main content

Pharmaceutical Quality Analytics, Powered by Entropy

Batch release testing, dissolution profiles, and stability studies all demand statistical rigor — often from small, non-normal datasets. EntropyStat provides audit-defensible distribution analysis that regulators can trust.

Industry Challenges

Batch Release Testing Bottlenecks

Each batch requires dissolution testing on 6–12 tablets. Classical statistics provide wide confidence intervals that delay release decisions and create regulatory risk.

Non-Normal Distributions in Biological Assays

Bioassay results are inherently skewed. Forcing normality assumptions into capability analysis produces misleading metrics that auditors flag during inspections.

Stability Study Small Samples

Accelerated and long-term stability studies have limited sample sizes per time point. Traditional methods cannot reliably compare distributions across conditions.

Regulatory Audit Readiness

FDA and EMA auditors expect statistically sound methods. When asked 'why did you use this technique?', you need a defensible answer — not 'because it was the default in our software.'

Standards & Compliance

FDA 21 CFR Part 11

Electronic records and signatures must be trustworthy. EntropyStat's reproducible, distribution-free analysis produces consistent results that satisfy data integrity requirements.

EU Annex 11

Computerized systems used in GMP environments must produce reliable results. Entropy-based methods are deterministic and reproducible — the same input always produces the same output.

ICH Q8/Q9/Q10

Quality by Design (QbD) requires understanding process variability. EntropyStat reveals true distribution shape and hidden clusters that parametric methods miss in development data.

USP <905> / <711>

Uniformity of dosage units and dissolution testing require statistical evaluation. Entropy methods provide reliable acceptance testing from the small sample sizes these tests mandate.

Example Use Cases

Dissolution Profile Analysis

A batch of 12 tablets is tested for dissolution rate at multiple time points. The dissolution profile must meet USP acceptance criteria, but with only 6–12 data points per time point, traditional parametric tests are unreliable.

EntropyStat's EGDF builds the actual dissolution distribution from 6–12 measurements. Comparison across batches uses entropy-based homogeneity testing rather than t-tests that assume normality. Hidden subpopulations (e.g., coating defects affecting some tablets) are detected by ELDF cluster analysis.

Stability Study Comparison

Accelerated stability (40°C/75% RH) and long-term stability (25°C/60% RH) data need comparison to predict shelf life. Each condition has only 3–6 measurements per time point.

Entropy-based distribution fitting works reliably with 3–6 measurements per condition. The KS-style comparison test quantifies how different the accelerated and long-term distributions are — without parametric assumptions that small-sample data cannot validate.

Sample dataset: Dissolution test results (% released) for 12 tablets at 30-minute time point — USP <711> compliance testing

Related Glossary Terms

Try EntropyStat with Pharmaceutical Data

Upload your data and see how EntropyStat outperforms traditional SPC methods. Free demo — no credit card required.